Center for Scientific Review; Notice of Closed Meetings, 57740-57741 [2018-24999]
Download as PDF
<![CDATA[
amozie on DSK3GDR082PROD with NOTICES
57740
Federal Register / Vol. 83, No. 222 / Friday, November 16, 2018 / Notices
James Berger, MS, MT (ASCP), SBB,
Senior Advisor for Blood and Tissue
Policy, Office of HIV/AIDS and
Infectious Disease Policy, Office of the
Assistant Secretary for Health, U.S.
Department of Health and Human
Services, 330 C Street SW, Room L001
Switzer Building, Washington, DC
20201.
FOR FURTHER INFORMATION CONTACT:
James Berger, MS, MT (ASCP), SBB,
Senior Advisor for Blood and Tissue
Policy; Telephone: (202) 795–7608; Fax:
(202) 691–2101; Email address:
tickbornedisease@hhs.gov. Website
information about activities of the
Working Group, as well as the charter
for the Working Group, which has been
filed with the Library of Congress, can
be found at https://www.hhs.gov/ash/
advisory-committees/tickbornedisease/
index.html.
SUPPLEMENTARY INFORMATION: Section
2062 of the 21st Century Cures Act
requires establishment of the Tick-Borne
Disease Working Group. The Working
Group is governed by provisions of the
Federal Advisory Committee Act, Public
Law 92–463, as amended (5 U.S.C.
App.), which sets forth standards for the
formation and use of federal advisory
committees. The 21st Century Cures Act
is intended to advance the research and
development of new therapies and
diagnostics and make substantial federal
investments in a wide range of health
priorities. The Working Group is a nondiscretionary federal advisory
committee.
Objectives and Scope of Activities.
The Secretary of Health and Human
Services is responsible for ensuring the
conduct of and support for
epidemiological, basic, translational,
and clinical research related to vectorborne diseases, including tick-borne
diseases. The Working Group provides
assistance for this effort. The Working
Group membership provides expertise
and reviews all efforts within the
Department of Health and Human
Services related to all tick-borne
diseases, to help ensure interagency
coordination and minimize overlap, and
to examine research priorities.
Membership and Designation. The
Working Group consists of 14 voting
members who represent diverse
scientific disciplines and views. The
composition includes seven federal
members and seven public members.
The federal members consist of one or
more representatives of each of the
following HHS agencies: Office of the
Assistant Secretary for Health, the Food
and Drug Administration, the Centers
for Disease Control and Prevention, and
the National Institutes of Health. The
VerDate Sep<11>2014
17:19 Nov 15, 2018
Jkt 247001
non-federal public members consist of
representatives of the following
categories: Physicians and other medical
providers with experience in diagnosing
and treating tick-borne diseases;
scientists or researchers with expertise;
patients and their family members; and
nonprofit organizations that advocate
for patients with respect to tick-borne
disease. Individuals who are appointed
to represent federal entities are
classified as regular government
employees. The public members are
classified as special government
employees. Invitations of membership is
extended to other agencies and offices of
the Department of Health and Human
Services and other individuals as
determined by the Secretary to be
appropriate and beneficial for
accomplishing the mission of the
Working Group.
The federal members are appointed to
serve for the duration of time that the
Working Group is authorized to operate.
Participation of the appointed federal
members is at the discretion of their
respective agency head. The public
members are invited to serve
overlapping terms of up to four years.
Any public member who is appointed to
fill the vacancy of an unexpired term
will be appointed to serve for the
remainder of that term. A non-federal
public member may serve after the
expiration of their term until their
successor has taken office, but no longer
than 180 days. Terms of more than two
years are contingent upon renewal of
the charter of the Working Group.
Pursuant to advance written agreement,
public members of the Working Group
will receive no stipend for the advisory
service that they render as members of
the Working Group. However, public
members will receive per diem and
reimbursement for travel expenses
incurred in relation to performing duties
for the Working Group, as authorized by
law under 5 U.S.C. 5703 for persons
who are employed intermittently to
perform services for the federal
government and in accordance with
federal travel regulations.
Estimated Number and Frequency of
Meetings. The Working Group will meet
not less than twice a year. The meetings
will be open to the public, except as
determined otherwise by the Secretary,
or another official to whom authority
has been delegated, in accordance with
the guidelines under Government in the
Sunshine Act, 5 U.S.C. 552b(c).
Nominations: Nominations, including
self-nominations, of individuals who
have the specified expertise and
knowledge will be considered for
appointment as public voting members
of the Working Group. A nomination
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
should include, at a minimum, the
following for each nominee: (1) A letter
of nomination that clearly states the
name and affiliation of the nominee, the
basis for the nomination, and a
statement from the nominee that
indicates that the individual is willing
to serve as a member of the Working
Group, if selected; (2) the nominator’s
name, address, and daytime telephone
number, and the address, telephone
number, and email address of the
individual being nominated; and (3) a
current copy of the nominee’s
curriculum vitae or resume, which must
be limited to no more than 10 pages.
Every effort will be made to ensure
that the Working Group is a diverse
group of individuals with representation
from various geographic locations, racial
and ethnic minorities, all genders, and
persons living with disabilities.
Individuals being considered for
appointment as public voting members
will be required to complete and submit
a report of their financial holdings. An
ethics review must be conducted to
ensure that individuals appointed as
public voting members of the Working
Group are not involved in any activity
that may pose a potential conflict of
interest for the official duties that are to
be performed. This is a federal ethics
requirement that must be satisfied upon
entering the position and annually
throughout the established term of
appointment on the Working Group.
Dated: November 5, 2018.
James J. Berger,
Senior Advisor for Blood and Tissue Policy,
Designated Federal Officer, Tick-Borne
Disease Working Group.
[FR Doc. 2018–25082 Filed 11–15–18; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\16NON1.SGM
16NON1
Federal Register / Vol. 83, No. 222 / Friday, November 16, 2018 / Notices
amozie on DSK3GDR082PROD with NOTICES
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: AIDS and AIDS Related Research.
Date: December 4, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796, bdey@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Structure/Function Relationships.
Date: December 6, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Peter B. Guthrie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC 7850, Bethesda, MD 20892, (301) 435–
1239, guthriep@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Adult Cognition, Perception, and
Psychopathology.
Date: December 6, 2018.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Wind Cowles, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3172,
Bethesda, MD 20892, 301–437–7872,
cowleshw@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Immunopathology and
Immunotherapy.
Date: December 6, 2018.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Nicholas J. Donato, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040,
Bethesda, MD 20892, 301–827–4810,
nick.donato@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Role of
Maternal-Child Interactions in Brain
Development Related Disorders.
Date: December 7, 2018.
Time: 11:00 a.m. to 12:30 p.m.
VerDate Sep<11>2014
17:19 Nov 15, 2018
Jkt 247001
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Seetha Bhagavan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5194,
MSC 7846, Bethesda, MD 20892, (301) 237–
9838, bhagavas@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–17–
340: HIV Protease Evolution and Drug
Resistance.
Date: December 7, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Eduardo A. Montalvo,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7852, Bethesda, MD 20892, (301) 435–
1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Molecular Cellular Endocrinology.
Date: December 10, 2018.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Liliana N. Berti-Mattera,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, RM 4215,
Bethesda, MD 20892, 301–827–7609,
liliana.berti-mattera@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: AIDS and AIDS Related Research.
Date: December 11, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796, bdey@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846– 93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 9, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–24999 Filed 11–15–18; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
57741
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel; NIAID, 2018 Omnibus BAA
(HHS–NIH–NIAID–BAA2018) Research Area
002: Advanced Development of Vaccine
Candidates for Biodefense and Emerging
Infectious Diseases.
Date: December 6–7, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Kelly Y. Poe, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3F40B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5036,
poeky@mail.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel; NIAID, SBIR Phase II
Clinical Trial Implementation Cooperative
Agreement (U44 Clinical Trial Required).
Date: December 14, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: J. Bruce Sundstrom, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G11A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, 240–669–5045,
sundstromj@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel; NIAID, Clinical Trial
Planning Grant (R34).
Date: December 18, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 83, Number 222 (Friday, November 16, 2018)]
[Notices]
[Pages 57740-57741]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24999]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which
[[Page 57741]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: AIDS and AIDS Related Research.
Date: December 4, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Barna Dey, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3184, Bethesda, MD 20892, 301-451-2796,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Structure/Function Relationships.
Date: December 6, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Peter B. Guthrie, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142, MSC 7850, Bethesda, MD
20892, (301) 435-1239, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Adult Cognition, Perception, and
Psychopathology.
Date: December 6, 2018.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Wind Cowles, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3172, Bethesda, MD 20892, 301-437-7872,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cancer Immunopathology and Immunotherapy.
Date: December 6, 2018.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Nicholas J. Donato, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040, Bethesda, MD 20892, 301-
827-4810, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Role of Maternal-Child Interactions in Brain Development
Related Disorders.
Date: December 7, 2018.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Seetha Bhagavan, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5194, MSC 7846, Bethesda, MD
20892, (301) 237-9838, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-17-340: HIV Protease Evolution and Drug Resistance.
Date: December 7, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Eduardo A. Montalvo, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108, MSC 7852, Bethesda, MD
20892, (301) 435-1168, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics in Molecular Cellular Endocrinology.
Date: December 10, 2018.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Liliana N. Berti-Mattera, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, RM 4215, Bethesda, MD 20892, 301-827-
7609, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: AIDS and AIDS Related Research.
Date: December 11, 2018.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Barna Dey, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3184, Bethesda, MD 20892, 301-451-2796,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846- 93.878, 93.892,
93.893, National Institutes of Health, HHS)
Dated: November 9, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-24999 Filed 11-15-18; 8:45 am]
BILLING CODE 4140-01-P
